Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 1
2010 1
2011 1
2012 1
2014 3
2015 4
2016 2
2018 2
2019 1
2020 3
2021 1
2022 6
2023 2
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D; GERICO&UCBG/Unicancer. Brain E, et al. Among authors: allouache d. Lancet. 2025 Aug 2;406(10502):489-500. doi: 10.1016/S0140-6736(25)00832-3. Lancet. 2025. PMID: 40752909 Clinical Trial.
Sleep macro- and microstructure in breast cancer survivors.
Perrier J, Duivon M, Clochon P, Rehel S, Doidy F, Grellard JM, Segura-Djezzar C, Geffrelot J, Emile G, Allouache D, Levy C, Polvent S, Viader F, Eustache F, Joly F, Giffard B. Perrier J, et al. Among authors: allouache d. Sci Rep. 2022 Feb 15;12(1):2557. doi: 10.1038/s41598-022-06664-z. Sci Rep. 2022. PMID: 35169245 Free PMC article.
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.
Laas E, Hamy AS, Bachelot T, Gougis P, Lemonnier J, André F, Cameron D, Bliss J, Chabaud S, Hardy-Bessard AC, Lacroix-Triki M, Allouache D, Debled M, Campone M, Venat-Bouvet L, Cottu P, Martinez M, Grenier J, Dalenc F, Dumas E, Reyal F, Asselain B, Penault-Llorca F, Lévi F, Giacchetti S. Laas E, et al. Among authors: allouache d. Clin Pharmacol Ther. 2025 Nov;118(5):1192-1201. doi: 10.1002/cpt.70030. Epub 2025 Aug 24. Clin Pharmacol Ther. 2025. PMID: 40849898 Clinical Trial.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Bachelot T, et al. Among authors: allouache d. J Clin Oncol. 2022 Nov 10;40(32):3699-3708. doi: 10.1200/JCO.21.02179. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605174 Clinical Trial.
Baseline cognitive functions among elderly patients with localised breast cancer.
Lange M, Giffard B, Noal S, Rigal O, Kurtz JE, Heutte N, Lévy C, Allouache D, Rieux C, Le Fel J, Daireaux A, Clarisse B, Veyret C, Barthélémy P, Longato N, Eustache F, Joly F. Lange M, et al. Among authors: allouache d. Eur J Cancer. 2014 Sep;50(13):2181-9. doi: 10.1016/j.ejca.2014.05.026. Epub 2014 Jun 20. Eur J Cancer. 2014. PMID: 24958735 Free article.
30 results